@article{HedrichHofmannPabliketal.2013, author = {Hedrich, Christian M. and Hofmann, Sigrun R. and Pablik, Jessica and Morbach, Henner and Girschick, Hermann J.}, title = {Autoinflammatory bone disorders with special focus on chronic recurrent multifocal osteomyelitis (CRMO)}, series = {Pediatric Rheumatology}, volume = {11}, journal = {Pediatric Rheumatology}, number = {47}, issn = {1546-0096}, doi = {10.1186/1546-0096-11-47}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-125694}, year = {2013}, abstract = {Sterile bone inflammation is the hallmark of autoinflammatory bone disorders, including chronic nonbacterial osteomyelitis (CNO) with its most severe form chronic recurrent multifocal osteomyelitis (CRMO). Autoinflammatory osteopathies are the result of a dysregulated innate immune system, resulting in immune cell infiltration of the bone and subsequent osteoclast differentiation and activation. Interestingly, autoinflammatory bone disorders are associated with inflammation of the skin and/or the intestine. In several monogenic autoinflammatory bone disorders mutations in disease-causing genes have been reported. However, regardless of recent developments, the molecular pathogenesis of CNO/CRMO remains unclear. Here, we discuss the clinical presentation and molecular pathophysiology of human autoinflammatory osteopathies and animal models with special focus on CNO/CRMO. Treatment options in monogenic autoinflammatory bone disorders and CRMO will be illustrated.}, language = {en} } @article{HedrichHofmannPabliketal.2013, author = {Hedrich, Christian M. and Hofmann, Sigrun R. and Pablik, Jessica and Morbach, Henner and Girschick, Hermann J.}, title = {Autoinflammatory bone disorders with special focus on chronic recurrent multifocal osteomyelitis (CRMO)}, series = {Pediatric Rheumatology}, volume = {11}, journal = {Pediatric Rheumatology}, number = {47}, doi = {10.1186/1546-0096-11-47}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-132456}, year = {2013}, abstract = {Sterile bone inflammation is the hallmark of autoinflammatory bone disorders, including chronic nonbacterial osteomyelitis (CNO) with its most severe form chronic recurrent multifocal osteomyelitis (CRMO). Autoinflammatory osteopathies are the result of a dysregulated innate immune system, resulting in immune cell infiltration of the bone and subsequent osteoclast differentiation and activation. Interestingly, autoinflammatory bone disorders are associated with inflammation of the skin and/or the intestine. In several monogenic autoinflammatory bone disorders mutations in disease-causing genes have been reported. However, regardless of recent developments, the molecular pathogenesis of CNO/CRMO remains unclear. Here, we discuss the clinical presentation and molecular pathophysiology of human autoinflammatory osteopathies and animal models with special focus on CNO/CRMO. Treatment options in monogenic autoinflammatory bone disorders and CRMO will be illustrated.}, language = {en} } @phdthesis{Krakow2021, author = {Krakow, S{\"o}ren}, title = {CD14-Reexpression definiert einen immunregulatorischen Phänotyp Monozyten-gereifter Zellen nach IL-10/R848-Stimulation}, doi = {10.25972/OPUS-22428}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-224280}, school = {Universit{\"a}t W{\"u}rzburg}, year = {2021}, abstract = {Dendritische Zellen k{\"o}nnen als antigenpr{\"a}sentierende Zellen sowohl immunogene als auch tolerogene Funktionen im Immunsystem wahrnehmen und werden in der Therapie von Tumorerkrankungen und Autoimmunerkrankungen eingesetzt. IL-10 gilt als Induktor tolerogener dendritischer Zellen. Diese werden in der Literatur oft als unreif bezeichnet und stehen im Gegensatz zu den reifen immunogenen dendritischen Zellen, die durch die Expression des Reifungsmarkers CD83 gekennzeichnet sind. Ausdifferenzierte dendritische Zellen exprimieren zudem das Antigen CD86, das der T-Zell-Aktivierung dient. In der vorliegenden Arbeit wurde der Einfluss von IL-10 auf den Reifungsprozess dendritischer Zellen in vitro untersucht. Zur Generierung unreifer dendritischer Zellen wurden humane Monozyten nach etabliertem Protokoll mit IL-4 und GM-CSF stimuliert. Nach anschließender IL-10-Stimulation, insbesondere in Kombination mit einem TLR-Agonisten, bildeten sich zwei exklusive Zellpopulationen: eine CD14+ Population und eine CD83+ Population. Unreife CD14-CD83- dendritische Zellen reexprimierten einerseits CD14 oder exprimierten andererseits CD83. Dabei zeigte sich, dass das kostimulierende Antigen CD86 gleichermaßen sowohl mit als auch ohne IL-10-Inkubation hoch exprimiert wurde und IL-10 folglich keinen zus{\"a}tzlichen Einfluss auf dessen Expression hat. Insgesamt waren Ver{\"a}nderungen bez{\"u}glich der Oberfl{\"a}chenantigene, die bei der Betrachtung der Gesamtheit aller Zellen auffallen, auf eine quantitative Verschiebung der beiden Zellpopulationen zur{\"u}ckzuf{\"u}hren. IL-10 beeinflusst also nicht direkt einzelne kostimulierende oder inhibitorische Molek{\"u}le, sondern beeinflusst den Anteil der CD14+ Zellen gegen{\"u}ber den CD83+ dendritischen Zellen. Funktionell betrachtet zeigten die CD14+ Zellen eine gesteigerte Makropinozytose im Gegensatz zu den reifen CD83+ dendritischen Zellen. Zusammenfassend f{\"u}hrt IL-10 zu einer Reexpression von CD14 auf unreifen dendritischen Zellen und aktiviert einen alternativen Differenzierungsweg. Die CD14+ Zellen weisen einen stabilen immunregulatorischen Ph{\"a}notyp auf und unterscheiden sich somit von reifen dendritischen Zellen, die nach Inkubation mit IL-10 nicht reguliert werden. Damit muss die Begrifflichkeit und Klassifikation tolerogener dendritischer Zellen weiter diskutiert werden.}, subject = {Dendritische Zelle}, language = {de} } @article{KrakowCrescimoneBartelsetal.2019, author = {Krakow, S{\"o}ren and Crescimone, Marie L. and Bartels, Charlotte and Wiegering, Verena and Eyrich, Matthias and Schlegel, Paul G. and W{\"o}lfl, Matthias}, title = {Re-expression of CD14 in response to a combined IL-10/TLR stimulus defines monocyte-derived cells with an immunoregulatory phenotype}, series = {Frontiers in Immunology}, volume = {10}, journal = {Frontiers in Immunology}, number = {1484}, doi = {10.3389/fimmu.2019.01484}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-201537}, year = {2019}, abstract = {Interleukin 10 is a central regulator of the antigen-presenting function of myeloid cells. It exerts immunomodulatory effects in vivo and induces a regulatory phenotype in monocyte-derived cells in vitro. We analyzed phenotype and function of monocytic cells in vitro in relation to the cytokine milieu and the timing of TLR-based activation. In GM-CSF/IL-4 cultured human monocytic cells, we identified two, mutually exclusive cell populations arising from undifferentiated cells: CD83\(^+\) fully activated dendritic cells and CD14\(^+\) macrophage like cells. Re-expression of CD14 occurs primarily after a sequential trigger with a TLR signal following IL-10 preincubation. This cell population with re-expressed CD14 greatly differs in phenotype and function from the CD83+ cells. Detailed analysis of individual subpopulations reveals that exogenous IL-10 is critical for inducing the shift toward the CD14\(^+\) population, but does not affect individual changes in marker expression or cell function in most cases. Thus, plasticity of CD14 expression, defining a subset of immunoregulatory cells, is highly relevant for the composition of cellular products (such as DC vaccines) as it affects the function of the total product.}, language = {en} } @article{NosterdeKoningMaieretal.2016, author = {Noster, Rebecca and de Koning, Heleen D. and Maier, Elisabeth and Prelog, Martina and Lainka, Elke and Zielinski, Christina E.}, title = {Dysregulation of proinflammatory versus anti-inflammatory human T\(_H\)17 cell functionalities in the autoinflammatory Schnitzler syndrome}, series = {Journal of Allergy and Clinical Immunology}, volume = {138}, journal = {Journal of Allergy and Clinical Immunology}, number = {4}, doi = {10.1016/j.jaci.2015.12.1338}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-187205}, pages = {1161-1169.e6}, year = {2016}, abstract = {Background: T\(_H\)17 cells have so far been considered to be crucial mediators of autoimmune inflammation. Two distinct types of T\(_H\)17 cells have been described recently, which differed in their polarization requirement for IL-1b and in their cytokine repertoire. Whether these distinct T\(_H\)17 phenotypes translate into distinct T\(_H\)17 cell functions with implications for human health or disease has not been addressed yet. Objective: We hypothesized the existence of proinflammatory and anti-inflammatory human T\(_H\)17 cell functions based on the differential expression of IL-10, which is regulated by IL-1 beta. Considering the crucial role of IL-1 beta in the pathogenesis of autoinflammatory syndromes, we hypothesized that IL-1 beta mediates the loss of anti-inflammatory T\(_H\)17 cell functionalities in patients with Schnitzler syndrome, an autoinflammatory disease. Methods: To assess proinflammatory versus anti-inflammatory T\(_H\)17 cell functions, we performed suppression assays and tested the effects of IL-1 beta dependent and independent T\(_H\)17 subsets on modulating proinflammatory cytokine secretion by monocytes. Patients with Schnitzler syndrome were analyzed for changes in T\(_H\)17 cell functions before and during therapy with IL-1 beta-blocking drugs. Results: Both T\(_H\)17 cell subsets differ in their ability to suppress T-cell proliferation and their ability to modulate proinflammatory cytokine production by antigen-presenting cells because of their differential IL-10 expression properties. In patients with Schnitzler syndrome, systemic overproduction of IL-1 beta translates into a profound loss of anti-inflammatory T\(_H\)17 cell functionalities, which can be reversed by anti-IL-1b treatment. Conclusion: IL-1 beta signaling determines the differential expression pattern of IL-10, which is necessary and sufficient to induce proinflammatory versus anti-inflammatory T\(_H\)17 cell functions. Our data introduce T\(_H\)17 cell subsets as novel players in autoinflammation and thus novel therapeutic targets in autoinflammatory syndromes including other IL-1 beta mediated diseases. This demonstrates for the first time alterations in the adaptive immune system in patients with autoinflammatory syndromes.}, language = {en} }